Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerDavid Cunningham, A. Norman, Naureen Starling et al.|New England Journal of Medicine|2008Cited by 2.3k
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialYolanda Barbáchano, Ian Chau, David Cunningham et al.|The Lancet Oncology|2013Cited by 728
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialHugo Ford, Janet Dunn, Andrea Marshall et al.|The Lancet Oncology|2013Cited by 604
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, John P. Neoptolemos, Jonathan Wadsley et al.|The Lancet Oncology|2014Cited by 374
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trialDavid Cunningham, Ruth E. Langley, Sally Stenning et al.|The Lancet Oncology|2017Cited by 286